Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer: Di Leo A, Jerusalem G, Petruzelka L, et al (Hosp of Prato, Italy; Centre Hospitalier Universitaire Sart Tilman, Liége, Belgium; AZ. Klina, Brasschaat, Belgium; Et al) J Clin Oncol 28:4594-4600, 2010